Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ehab Atallah

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Leukemia Research|February 22, 2011
Nilotinib cardiac toxicity: should we still be concerned?Ehab Atallah
Haematologica|October 12, 2023
Eligibility criteria: too big, too small or just right?Ehab Atallah
Haematologica|July 21, 2022
Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest?Ehab Atallah
Clinical Lymphoma, Myeloma & Leukemia|June 8, 2019
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy CessationVamsi Kota, Ehab Atallah
Current Opinion in Hematology|January 27, 2007
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phaseEhab Atallah, Jorge Cortes
Expert Review of Anticancer Therapy|May 19, 2009
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasmsEhab Atallah, Srdan Verstovsek
Seminars in Hematology|July 23, 2009
Practical considerations for the management of patients in the tyrosine kinase inhibitor eraMichael O'Dwyer, Ehab Atallah
Expert Opinion on Emerging Drugs|November 29, 2012
Emerging drugs for myelofibrosisEhab Atallah, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|January 9, 2018
Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future?Ehab Atallah, Ellen Ritchie
Expert Opinion on Investigational Drugs|April 10, 2021
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?Talha Badar, Ehab Atallah
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Leukemia Research|February 22, 2011
Nilotinib cardiac toxicity: should we still be concerned?Ehab Atallah
Haematologica|October 12, 2023
Eligibility criteria: too big, too small or just right?Ehab Atallah
Haematologica|July 21, 2022
Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest?Ehab Atallah
Clinical Lymphoma, Myeloma & Leukemia|June 8, 2019
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy CessationVamsi Kota, Ehab Atallah
Current Opinion in Hematology|January 27, 2007
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phaseEhab Atallah, Jorge Cortes
Expert Review of Anticancer Therapy|May 19, 2009
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasmsEhab Atallah, Srdan Verstovsek
Seminars in Hematology|July 23, 2009
Practical considerations for the management of patients in the tyrosine kinase inhibitor eraMichael O'Dwyer, Ehab Atallah
Expert Opinion on Emerging Drugs|November 29, 2012
Emerging drugs for myelofibrosisEhab Atallah, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|January 9, 2018
Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future?Ehab Atallah, Ellen Ritchie
Expert Opinion on Investigational Drugs|April 10, 2021
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?Talha Badar, Ehab Atallah
Pageof 11